2021 ACCP Virtual Journal Club March | Discordance between Child Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications for Dosing Recommendations of Oncology Compounds - LIVE
Includes a Live Event on 03/17/2021 at 2:00 PM (EDT)
Discordance Between Child-Pug and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds- LIVE
ACCP Virtual Journal Club Webinars
Live Session: Wednesday, March 17, 2021 from 2:00-3:00 PM ET
On Demand: March 17, 2021 to March 17, 2024
See Handouts tab for Continuing Education information on IPCE credits.
Mohamed Elmeliegy, PhD
Dr. Mohamed Elmeliegy holds a position as Associate Director, Oncology Clinical Pharmacology Dept at Pfizer where he provides clinical pharmacology and pharmacometrics input for different phases of development for small molecules, monoclonal antibodies, bispecifics, biosimilars and follow-on biologics. Dr. Elmeliegy also holds an Adjunct Assistant Professor positions in the Univ at Buffalo (UB) and the Univ of California, San Diego (UCSD) where he administers workshops on clinical pharmacology and collaborates on scientific research with faculty members. He received his PhD from Saint Jude Children Research Hosp and the Univ of Tennessee at Memphis. He completed a post-doctoral fellowship with Drs. Wojciech Krzyzanski and William J. Jusko at UB. Prior to joining Pfizer, he held several positions in the Oncology Clinical Pharmacology Dept in Novartis.
Nursat Shafiq, MD (Moderator)
Post Graduate Inst of Medical Education & Research
After completing her medical training, Dr. Nursat Shafiq pursued her specialization in clinical pharmacology . She is a Professor in the Department of Pharmacology at Postgraduate Inst of Medical Education & Research, a tertiary care teaching hospital in India. Currently she is taking care of the Clinical Pharmacology Unit in the hospital and the antimicrobial stewardship activities. Her research interests include tuberculosis and other infections due to multidrug resistant organisms and is currently involved in interventional, multi-centric trials and PK-PD studies in this area. Dr. Shafiq is involved in multidisciplinary clinical rounds in special groups of patients such as critically ill, pediatric and those with hepatic/renal impairment. As faculty in the Institute, she is involved in providing clinical pharmacology training to medical postgraduates. Dr. Shafiq serves on various committees for antimicrobial use at regional and national level.
|Access Date||Quiz Result||Score||Actions|